Last updated: 2026-09-09 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Xeris Biopharma Holdings, Inc. (XERS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8,48, with a market capitalization of $1,56B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5,25 to $10,08. This page covers its latest market performance, valuation, price trends and company information.
$1,56B | |
$8,39 | |
$27,98 | |
$0,97 | |
$8,53 | |
972,88K | |
1,86M | |
-- | |
$10,08 | |
$5,25 | |
-- | |
-- |
Xeris Biopharma Holdings, Inc. (XERS) last closed at $8,53 as of 2026-09-08 23:31:00, unchanged from the previous close of $8,53.
During the latest regular trading session, XERS traded between $0,97 and $27,98, with a volume of 972,88K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Xeris Biopharma Holdings, Inc. (XERS) moved from $8,60 to $8,48, representing a decline of 1,45% ($0,13).
The stock traded between $8,22 and $8,78 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1,26 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66,8%
XERS is currently trading at $8,48, placing it 66,8% of the way from its 52-week low of $5,25 to its 52-week high of $10,08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 435 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xeris Biopharma Holdings, Inc. (XERS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.